Plesnila Nikolaus
Institute for Stroke and Dementia Research and Munich Cluster of System Neurology (Synergy), University of Munich Medical Center, Munich, Germany.
Curr Opin Pharmacol. 2016 Feb;26:110-7. doi: 10.1016/j.coph.2015.10.008. Epub 2015 Nov 21.
Traumatic brain injury (TBI) is the major cause of death in children and young adults and one of the major reasons for long-term disability worldwide, however, no specific clinical treatment option could be established so far. This is surprising since it is well known that following the initial mechanical damage to the brain a plethora of delayed processes are activated which ultimately result in additional brain damage. Among these secondary mechanisms, acute and chronic activation of the innate and adaptive immune system is increasingly believed to play an important role for the pathogenesis of TBI. Understanding these processes may results in new, clinically applicable therapeutic options for TBI patients.
创伤性脑损伤（TBI）是儿童和青壮年死亡的主要原因，也是全球长期残疾的主要原因之一，然而，迄今为止尚未确立具体的临床治疗方案。这令人惊讶，因为众所周知，在大脑受到初始机械损伤后，会激活大量延迟过程，最终导致额外的脑损伤。在这些继发性机制中，先天性和适应性免疫系统的急性和慢性激活越来越被认为在TBI的发病机制中起重要作用。了解这些过程可能会为TBI患者带来新的、可临床应用的治疗选择。
